Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, with a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo. The primary endpoint of the ...
The La Jolla, California-based biotech licensed its first drug – itolizumab for graft-versus-host disease (GvHD), asthma and lupus nephritis – from Indian drugmaker Biocon in 2017. The Bioniz ...
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...
The study, which was co-sponsored with Biocon (NSE:BION) Limited, included a total of 90 biologic-naïve patients who were randomized to receive either itolizumab, a placebo, or adalimumab ...
Equillium, Inc., a clinical-stage biotechnology company, and Biocon have announced positive topline results from the phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
The data suggests high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio (UPCR) when itolizumab was added t ...
Equillium’s itolizumab downregulates T effector cell activity and trafficking to tissues. It is currently being tested against acute graft-vs-host disease (aGVHD), lupus nephritis, and ...